Sickle Cell Researcher Accelerates Drug Discovery with Atomwise Virtual Screening

November 29, 2021

Safo’s team challenged Atomwise’s technology to identify activators and inhibitors for potential targets for sickle cell disease. One target, erythrocyte pyruvate kinase, is part of the glycolysis cycle and is associated with a metabolite that has an allosteric effect on hemoglobin, amplifying symptoms for sickle cell patients. Activating pyruvate kinase could indirectly reduce the metabolite levels and minimize disease impact. On the other hand, inhibiting this target has been shown to impair the survival of cancer cells. Click for entire blog.